These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

274 related articles for article (PubMed ID: 34483213)

  • 1. Characteristics of Ischemic Versus Hemorrhagic Stroke in Patients Receiving Oral Anticoagulants: Results of the PASTA Study.
    Suda S; Abe A; Iguchi Y; Yagita Y; Kanzawa T; Okubo S; Ohara N; Mizunari T; Yamazaki M; Nakajima N; Kondo K; Fujimoto S; Inoue T; Iwanaga T; Terasawa Y; Shibazaki K; Kono Y; Nakajima M; Nakajima M; Mishina M; Adachi K; Imafuku I; Nomura K; Nagao T; Yaguchi H; Okamoto S; Osaki M; Kimura K
    Intern Med; 2022 Mar; 61(6):801-810. PubMed ID: 34483213
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Vitamin K antagonists but not non-vitamin K antagonists in addition on antiplatelet therapy should be associated with increase of hematoma volume and mortality in patients with intracerebral hemorrhage: A sub-analysis of PASTA registry study.
    Nomura K; Suda S; Abe A; Iguchi Y; Yagita Y; Kanzawa T; Okubo S; Fujimoto S; Kimura K;
    J Neurol Sci; 2023 May; 448():120643. PubMed ID: 37028263
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Predictors of intracranial hemorrhage in patients with atrial fibrillation treated with oral anticoagulants: Insights from the GARFIELD-AF and ORBIT-AF registries.
    Lim TW; Camm AJ; Virdone S; Singer DE; Bassand JP; Fonarow GC; Fox KAA; Ezekowitz M; Gersh BJ; Kayani G; Hylek EM; Kakkar AK; Mahaffey KW; Pieper KS; Peterson ED; Piccini JP;
    Clin Cardiol; 2023 Nov; 46(11):1398-1407. PubMed ID: 37596725
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Fatal intracranial haemorrhage occurring after oral anticoagulant treatment initiation for secondary stroke prevention in patients with atrial fibrillation.
    Tsivgoulis G; Katsanos AH; Seiffge DJ; Paciaroni M; Wilson D; Koga M; Macha K; Cappellari M; Kallmünzer B; Polymeris AA; Toyoda K; Caso V; Werring DJ; Engelter ST; De Marchis GM;
    Eur J Neurol; 2020 Aug; 27(8):1612-1617. PubMed ID: 32333493
    [TBL] [Abstract][Full Text] [Related]  

  • 5. How do anticoagulated atrial fibrillation patients who suffer ischemic stroke or spontaneous intracerebral hemorrhage differ?
    Lehtola H; Hartikainen J; Hartikainen P; Kiviniemi T; Nuotio I; Palomäki A; Ylitalo A; Airaksinen KEJ; Mustonen P
    Clin Cardiol; 2018 May; 41(5):608-614. PubMed ID: 29745996
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Association of Ischemic Stroke, Major Bleeding, and Other Adverse Events With Warfarin Use vs Non-vitamin K Antagonist Oral Anticoagulant Use in Patients With Atrial Fibrillation With a History of Intracranial Hemorrhage.
    Tsai CT; Liao JN; Chiang CE; Lin YJ; Chang SL; Lo LW; Hu YF; Tuan TC; Chung FP; Chao TF; Lip GYH; Chen SA
    JAMA Netw Open; 2020 Jun; 3(6):e206424. PubMed ID: 32478848
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effectiveness and Safety of Non-vitamin K Antagonist Oral Anticoagulants for Atrial Fibrillation and Venous Thromboembolism: A Systematic Review and Meta-analyses.
    Almutairi AR; Zhou L; Gellad WF; Lee JK; Slack MK; Martin JR; Lo-Ciganic WH
    Clin Ther; 2017 Jul; 39(7):1456-1478.e36. PubMed ID: 28668628
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Safety and efficacy of non-vitamin K oral anticoagulant treatment compared with warfarin in patients with non-valvular atrial fibrillation who develop acute ischemic stroke or transient ischemic attack: a multicenter prospective cohort study (daVinci study).
    Saji N; Kimura K; Tateishi Y; Fujimoto S; Kaneko N; Urabe T; Tsujino A; Iguchi Y;
    J Thromb Thrombolysis; 2016 Nov; 42(4):453-62. PubMed ID: 27207691
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Association of Intracerebral Hemorrhage Among Patients Taking Non-Vitamin K Antagonist vs Vitamin K Antagonist Oral Anticoagulants With In-Hospital Mortality.
    Inohara T; Xian Y; Liang L; Matsouaka RA; Saver JL; Smith EE; Schwamm LH; Reeves MJ; Hernandez AF; Bhatt DL; Peterson ED; Fonarow GC
    JAMA; 2018 Feb; 319(5):463-473. PubMed ID: 29372247
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Early or late initiation of dabigatran versus vitamin-K-antagonists in acute ischemic stroke or TIA: The PRODAST study.
    Grosse GM; Hüsing A; Stang A; Kuklik N; Brinkmann M; Nabavi D; Sparenberg P; Weissenborn K; Gröschel K; Royl G; Poli S; Michalski D; Eschenfelder CC; Weimar C; Diener HC;
    Int J Stroke; 2023 Dec; 18(10):1169-1177. PubMed ID: 37306492
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Ischemic Stroke and Transient Ischemic Attack Risk Following Vitamin K Antagonist Cessation in Newly Diagnosed Atrial Fibrillation: A Cohort Study.
    Martinez C; Wallenhorst C; Rietbrock S; Freedman B
    J Am Heart Assoc; 2020 Jan; 9(2):e014376. PubMed ID: 31937194
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Differences Between Anticoagulated Patients With Ischemic Stroke Versus Intracerebral Hemorrhage.
    Schaub F; Polymeris AA; Schaedelin S; Hert L; Meya L; Thilemann S; Traenka C; Wagner B; Seiffge D; Gensicke H; De Marchis GM; Bonati L; Engelter ST; Peters N; Lyrer P
    J Am Heart Assoc; 2022 Jan; 11(1):e023345. PubMed ID: 34935409
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Three-month risk-benefit profile of anticoagulation after stroke with atrial fibrillation: The SAMURAI-Nonvalvular Atrial Fibrillation (NVAF) study.
    Arihiro S; Todo K; Koga M; Furui E; Kinoshita N; Kimura K; Yamagami H; Terasaki T; Yoshimura S; Shiokawa Y; Kamiyama K; Takizawa S; Okuda S; Okada Y; Nagakane Y; Kameda T; Hasegawa Y; Shibuya S; Ito Y; Nakashima T; Takamatsu K; Nishiyama K; Matsuki T; Homma K; Takasugi J; Tokunaga K; Sato S; Kario K; Kitazono T; Toyoda K;
    Int J Stroke; 2016 Jul; 11(5):565-74. PubMed ID: 26927811
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Net Clinical Benefit of Non-Vitamin K Antagonist vs Vitamin K Antagonist Anticoagulants in Elderly Patients with Atrial Fibrillation.
    Patti G; Pecen L; Lucerna M; Huber K; Rohla M; Renda G; Siller-Matula J; Ricci F; Kirchhof P; De Caterina R
    Am J Med; 2019 Jun; 132(6):749-757.e5. PubMed ID: 30664837
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Factors associated with non-vitamin K antagonist oral anticoagulants for stroke prevention in patients with new-onset atrial fibrillation: Results from the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation II (ORBIT-AF II).
    Steinberg BA; Shrader P; Thomas L; Ansell J; Fonarow GC; Gersh BJ; Hylek E; Kowey PR; Mahaffey KW; O'Brien EC; Singer DE; Peterson ED; Piccini JP;
    Am Heart J; 2017 Jul; 189():40-47. PubMed ID: 28625380
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Quality of life and patient satisfaction in patients with atrial fibrillation on stable vitamin K antagonist treatment or switched to a non-vitamin K antagonist oral anticoagulant during a 1-year follow-up: A PREFER in AF Registry substudy.
    De Caterina R; Brüggenjürgen B; Darius H; Köhler S; Lucerna M; Pecen L; Renda G; Schilling RJ; Schliephacke T; Zamorano JL; Le Heuzey JY; Kirchhof P
    Arch Cardiovasc Dis; 2018 Feb; 111(2):74-84. PubMed ID: 28942115
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Non-vitamin K antagonist oral anticoagulants versus vitamin K antagonists in atrial fibrillation patients with previous stroke or intracranial hemorrhage: A systematic review and meta-analysis of observational studies.
    Guo Z; Ding X; Ye Z; Chen W; Chen Y
    Clin Cardiol; 2021 Jul; 44(7):917-924. PubMed ID: 34013988
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Differences in knowledge among patients with atrial fibrillation receiving non-vitamin K antagonist oral anticoagulants and vitamin K antagonists.
    Konieczyńska M; Sobieraj E; Bryk AH; Dębski M; Polak M; Podolec P; Małecka B; Pająk A; Desteghe L; Heidbuchel H; Undas A
    Kardiol Pol; 2018; 76(7):1089-1096. PubMed ID: 29528483
    [TBL] [Abstract][Full Text] [Related]  

  • 19. An updated meta-analysis of novel oral anticoagulants versus vitamin K antagonists for uninterrupted anticoagulation in atrial fibrillation catheter ablation.
    Cardoso R; Knijnik L; Bhonsale A; Miller J; Nasi G; Rivera M; Blumer V; Calkins H
    Heart Rhythm; 2018 Jan; 15(1):107-115. PubMed ID: 28917562
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Selection, management, and outcome of vitamin K antagonist-treated patients with atrial fibrillation not switched to novel oral anticoagulants. Results from the Dresden NOAC registry.
    Michalski F; Tittl L; Werth S; Hänsel U; Pannach S; Sahin K; Weiss N; Beyer-Westendorf J
    Thromb Haemost; 2015 Nov; 114(5):1076-84. PubMed ID: 25994496
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.